Scheduled Products Manufacturing Fees was Elite Pharmaceuticals’s largest product and service line in fiscal 2026, bringing in $141.47M of $148.87M (95%).
| Product and Service | FY 2011 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scheduled Products Manufacturing Fees | — | — | $74.76M | $141.47M | |||||||
| Manufacturing | $29.19M | $54.12M | — | — | |||||||
| Generic Products Anda | — | — | — | — | |||||||
| Unscheduled Products Manufacturing Fees | — | — | $7.23M | $6.34M | |||||||
| Manufactured Product, Other | — | — | — | — | |||||||
| Lodrane Products | — | — | — | — | |||||||
| Licensing | $4.97M | $2.50M | — | — | |||||||
| License & Service | — | — | — | — | |||||||
| Branded Products Nda | — | — | — | — | |||||||
| Unscheduled Products Licensing Fees | — | — | $1.81M | $594.49K | |||||||
| Scheduled Products Licensing Fees | — | — | $248.79K | $465.51K | |||||||
| Total | $34.16M | $56.63M | $84.04M | $148.87M |
Elite Pharmaceuticals brought in $148.87M from its four product and service lines in fiscal 2026, the year ended March 31, 2026. That was up 77.1% from $84.04M in fiscal 2025. Scheduled Products Manufacturing Fees was the largest at $141.47M (95.0%), ahead of Unscheduled Products Manufacturing Fees at $6.34M (4.3%) and Unscheduled Products Licensing Fees at $594.49K (0.4%). The remaining line, Scheduled Products Licensing Fees, brought in $465.51K.
Compared with fiscal 2025, Scheduled Products Manufacturing Fees grew 89.2% to $141.47M, while Unscheduled Products Manufacturing Fees fell 12.2% to $6.34M.
Elite Pharmaceuticals began breaking out Scheduled Products Manufacturing Fees in fiscal 2025, Unscheduled Products Manufacturing Fees in fiscal 2025, Unscheduled Products Licensing Fees in fiscal 2025 and Scheduled Products Licensing Fees in fiscal 2025. Elite Pharmaceuticals stopped reporting Manufacturing ($54.12M in fiscal 2024) and Licensing ($2.50M in fiscal 2024) as separate lines.
Manufacturing Fees was Elite Pharmaceuticals’s largest revenue line in fiscal 2021, bringing in $21.00M of $25.38M (83%).
| Fees | FY 2020 | FY 2021 |
|---|---|---|
| Manufacturing Fees | $14.53M | $21.00M |
| Licensing Fees | $3.47M | $4.38M |
| Total | $17.99M | $25.38M |
Elite Pharmaceuticals brought in $25.38M from its two revenue lines in fiscal 2021, the year ended March 31, 2021. That was up 41.0% from $17.99M in fiscal 2020. Manufacturing Fees was the largest at $21.00M (82.7%), ahead of Licensing Fees at $4.38M (17.3%).
Compared with fiscal 2020, Manufacturing Fees grew 44.5% to $21.00M and Licensing Fees grew 26.4% to $4.38M.
Elite Pharmaceuticals (ELTP) reports its revenue by product and service and by fees. In fiscal 2026, Scheduled Products Manufacturing Fees was its largest product and service line, bringing in $141.47M (95.0% of the total), followed by Unscheduled Products Manufacturing Fees at $6.34M (4.3%).
Scheduled Products Manufacturing Fees was Elite Pharmaceuticals' largest product and service line in fiscal 2026, bringing in $141.47M, or 95.0% of the $148.87M total across its four product and service lines.
Manufacturing Fees was Elite Pharmaceuticals' largest revenue line in fiscal 2021, bringing in $21.00M, or 82.7% of the $25.38M total across its two revenue lines.
Scheduled Products Manufacturing Fees grew faster than Unscheduled Products Manufacturing Fees in fiscal 2026, up 89.2% from $74.76M to $141.47M. Unscheduled Products Manufacturing Fees fell 12.2% to $6.34M.
Every figure comes from Elite Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Elite Pharmaceuticals gives it, and years follow its fiscal calendar.
Elite Pharmaceuticals' revenue by product and service goes back to fiscal 2011, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.